NorthStar Medical Radioisotopes has amended and expanded its existing collaboration with Monopar Therapeutics, the company announced recently.

According to a release, the long-term, non-exclusive master supply agreement states that NorthStar will provide Monopar with therapeutic radioisotope actinium-225 (Ac-225) for its development and potential future commercial programs.

“Using our proprietary electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) Ac-225,” NorthStar CEO Frank Scholz said in a statement. “We’re delighted to continue and extend our collaboration with Monopar and support development of its exciting MNPR-101 radiopharma platform focused on therapeutic agents to treat aggressive cancers.”

The amendment also aligns intellectual property rights.